Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies.


Autoria(s): Bello Claudia; Cea Michele; Dal Bello Giovanna; Garuti Anna; Rocco Ilaria; Cirmena Gabriella; Moran Eva; Nahimana Aimable; Duchosal Michel A.; Fruscione Floriana; Pronzato Paolo; Grossi Francesco; Patrone Franco; Ballestrero Alberto; Dupuis Marc; Sordat Bernard; Nencioni Alessio; Vogel Pierre
Data(s)

2010

Resumo

Novel alpha-mannosidase inhibitors of the type (2R,3R,4S)-2-({[(1R)-2-hydroxy-1-arylethyl]amino}methyl)pyrrolidine-3,4-diol have been prepared and assayed for their anticancer activities. Compound 30 with the aryl group=4-trifluoromethylbiphenyl inhibits the proliferation of primary cells and cell lines of different origins, irrespective of Bcl-2 expression levels, inducing a G2/Mcell cycle arrest and by modification of genes involved in cell cycle progression and survival.

Identificador

http://serval.unil.ch/?id=serval:BIB_FE0F7F1D0119

isbn:1464-3391[electronic], 0968-0896[linking]

pmid:20346684

doi:10.1016/j.bmc.2010.03.009

isiid:000277083400034

Idioma(s)

en

Fonte

Bioorganic and Medicinal Chemistry, vol. 18, no. 9, pp. 3320-3334

Palavras-Chave #Glycosylation; Alpha-Mannosidase Inhibitors; Antiproliferative Effects; Cell Cycle; Haematological Malignances; N-Linked Glycans; Endoplasmic-Reticulum; Human Glioblastoma; Cell Survival; Cancer-Cells; Glycosylation; Swainsonine; Lymphoma; Growth; BCL-2
Tipo

info:eu-repo/semantics/article

article